HRSA-J&J Dispute Over 340B Rebate Plan Again Underscores Need For Program Reform

 
• By Cathy Kelly
  
J&J is providing 340B Rebates Instead Of Discounts For Stelara and Xarelto. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access